Purpose
Help distinguish patients with poorly controlled disease from patients with well-controlled disease.1
Suspect SM Systemic Mastocytosis
For US healthcare professionals only
Get an accurate assessment of disease control with the Mastocytosis Control Test (MCT)1*
The MCT is a validated, self-administered, 5-question patient-reported tool designed to assess disease control in adult patients with non-advanced systemic mastocytosis (SM), including indolent systemic mastocytosis (ISM). The MCT serves as a resource for you and your patients in supporting disease management.1
Mastocystosis Control Test (MCT)
Instructions and Scoring†
For HCP use and interpretation
Download the MCT Instructions and Scoring
What makes the MCT valuable in clinical practice?
Design
A 5-question, self-administered survey that can be completed in daily clinical practice, with a one-page instruction sheet that can help interpret results.1†
Interpretation
A total MCT score of ≤12 may indicate poor disease control.1
Use case
Provides a framework for discussing symptoms that may otherwise go unspoken and shared decision-making on disease management.1
- *The MCT was developed at Charité by a team led by PD Dr. Frank Siebenhaar, PD Dr. Karsten Weller and Prof. Dr. Marcus Maurer with Dr. Cem Akin as a co-author. Blueprint Medicines (BPM) has secured a commercial license for distribution of this test to US healthcare providers only. If you have any questions on how this test was developed, please refer to the publication below and/or BPM Medical Information at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768).
- †Instructions are for US HCPs only and not to be shared with patients.